Health Condition 1: null- Coloon cancer Rectal cancer Stomach cancer endometrial cancer
Conditions
Interventions
Intervention1: Not Applicable: Not Applicable
Sponsors
Lexent Bio Inc
Eligibility
Inclusion criteria
Inclusion criteria: Age 18 years or older 1 Able to understand and grant informed consent 2 Able to have their blood drawn at enrolment 3 Registration and blood draw should be before surgery for patients with surgically resectable disease or before initiation of active therapy with non resectable disease 4 Prior therapy is allowed as long as there is locally advanced or metastatic measurable and/or non measurable but evaluable disease progression orrecurrence since last treatment 5 Availability of tissue sections or tumour containing tissue block either from a previously obtained or planned surgery. 6 Biopsy confirmed adenocarcinoma of the colon or rectum, endometrial cancers, or adenocarcinoma of the stomach including gastroesophageal adenocarcinomas
Exclusion criteria
Exclusion criteria: Unable to grant informed consent or comply with all study procedures Only non measurable or non evaluable disease at the time of blood collection Non-malignant tumors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 100% Quantification of MSI content in cfDNA and tissueTimepoint: Six Months | — |
Secondary
| Measure | Time frame |
|---|---|
| The MSI status of the study population will be summarised using descriptive statisticsTimepoint: Six Months | — |
Countries
India
Contacts
Public Contactsmita singhania PhD
Lexent Bio Inc
Outcome results
None listed